About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kirby McInerney LLP Reminds iRhythm Technologies, Inc. (IRTC) Investors of Class Action Filing and Encourages Investors to Contact the Firm

By: via Business Wire

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired iRhythm Technologies, Inc. (“iRhythm” or the “Company) (NASDAQ: IRTC) securities during the period from January 11, 2022 through May 30, 2023, inclusive. Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[Click here to learn more about the class action]

On November 1, 2022, iRhythm revised fourth quarter and full-year guidance, explaining during a conference call that it voluntarily issued a Customer Advisory Notice to its Zio AT customers. Consequently, the Company reduced its Zio AT forecast for the quarter from the 40% growth target it had provided throughout the past three quarters to 20%. On this news, the price of iRhythm shares declined by $14.07 per share, or approximately 11.6%, from $121.17 per share on November 2, 2022 to close at $107.10 on November 3, 2022.

On November 4, 2022, the Company disclosed that it initiated the Customer Advisory Notice on September 28, 2022, following issues raised by the FDA during an inspection that culminated in an inspection observation report on Form 483, and that the Customer Advisory Notice warned patients of a labeling correction related to the device’s maximum transmission limits during wear, as well as other critical issues that prevent the device from working as advertised. On this news, the price of iRhythm shares further declined by $2.43 per share, or approximately 2.4%, from $102.87 per share on November 4, 2022 to close at $100.44 on November 7, 2022.

Then, on May 4, 2023, the Company announced that it received a Subpoena Duces Tecum from the Consumer Protection Branch of the U.S. Department of Justice on April 4, 2023. Although the Company refrained from providing additional detail about the DOJ’s request, in a May 5, 2023, report, J.P. Morgan analysts noted that one of iRhythm’s competitors, Boston Scientific, had also disclosed that it received a subpoena from the DOJ relating to its real-time monitoring product, which indicated to the analysts that the DOJ investigation into iRhythm was related to the Zio AT. On this news, the price of iRhythm shares declined by $9.25 per share, or approximately 6.9%, from $134.04 per share on May 4, 2023 to close at $124.79 on May 5, 2023.

Finally, on May 30, 2023, iRhythm disclosed that it had received a warning letter from the FDA, which addressed several serious issues tied to the marketing and capabilities of the Zio AT device. In particular, the FDA noted that iRhythm had falsely marketed the Zio AT as approved for use in high-risk patients that require real-time cardiac monitoring. In truth, according to the FDA, Zio AT is only approved for long-term monitoring of arrhythmia events for non-critical care patients where real-time monitoring is not needed. On this news, the price of iRhythm shares declined by $7.41 per share, or approximately 6.1%, from $121.68 per share on May 30, 2023 to close at $114.27 on May 31, 2023.

The lawsuit alleges that, throughout the Class Period, iRhythm failed to disclose serious issues with its Zio AT heart monitor to the FDA, patients, or investors. The Company falsely represented the Zio AT as a real-time monitor intended for a target audience of high-risk patients and touted its potential growth as an innovative product that had only begun to penetrate the market for real-time monitoring, which investors looked upon favorably given the premium selling price associated with devices approved for high-risk patients. As a result of these representations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

If you purchased or otherwise acquired iRhythm securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

More News

View More
Why Seagate Is Wall Street's New Favorite AI Infrastructure Play
Via MarketBeat
Topics Artificial Intelligence
Tickers BAC STX
3 AI Infrastructure Stocks With Upside After the Summer Rally
Via MarketBeat
Topics Artificial Intelligence
Tickers AMZN ANET AVGO GOOGL META MSFT
Can Advantage2 Help Overcome D-Wave's Share Price Plateau?
Via MarketBeat
Tickers F GEV NVDA QBTS
Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything
Via MarketBeat
Tickers LLY
The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?
Via MarketBeat
Topics ETFs Economy Stocks
Tickers NVDA SNOW SPY WDAY
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.